Advertisement
News
Advertisement

TriReme Medical Announces Japanese Alliance

Sun, 01/09/2011 - 7:34pm
Bio-Medicine.Org

PLEASANTON Calif., SINGAPORE and TOKYO, Jan. 10, 2011 /PRNewswire/ -- TriReme Medical, Inc. (TriReme) today announced that it has signed an exclusive distribution and sales agreement for TriReme's complete line of advanced peripheral and coronary balloon dilatation catheters with Century Medical, Inc. (CMI), a leading independent device distributor for the important Japanese market.

TriReme recently received clearance from the U.S. Food and Drug Administration (FDA) for the GliderXtreme™ PTA balloon catheter, a highly differentiated balloon catheter with an expanded matrix of sizes including longer balloon lengths, an atraumatic tapered tip and shaft construction reinforced for torque transmission and exceptional pushability.  GliderXtreme™ is designed to cross difficult and highly diseased lesions to restore blood flow in the complex peripheral anatomy. TriReme's coronary version of this product, known as the Glider™ PTCA balloon catheter is a state-of-the-art catheter designed to overcome the limitations of conventional balloon catheters in treating complex disease by improving torque and push transmission. The combined PTCA & PTA balloon markets represent more than a $400 million catheter device revenue opportunity in Japan.

"CMI's long and successful history of obtaining timely regulatory approvals , launching new products , building strong dedicated sales and marketing teams and rapidly expanding market share makes it an ideal partner for us in Japan," Dr. Eitan Konstantino, President and CEO of TriReme said. "This agreement is a critical step in the realization of our Asian strategy. We look forward to working with CMI to develop this important market and to move market adoption to TriReme's line of product."

Akira Hoshino, President and CEO of CMI, commented that, "We are very pleased to have entered into this long-term distribution agreement with TriReme.  TriReme has proven itself quite capable of cre

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading